- Report
- March 2025
- 187 Pages
Global
From €3348EUR$3,545USD£2,848GBP
€3720EUR$3,939USD£3,164GBP
- Report
- October 2024
- 192 Pages
Global
From €3348EUR$3,545USD£2,848GBP
€3720EUR$3,939USD£3,164GBP
- Report
- September 2024
- 100 Pages
Global
From €5619EUR$5,950USD£4,779GBP
- Report
- August 2024
- 100 Pages
Global
From €5619EUR$5,950USD£4,779GBP
- Report
- April 2025
- 193 Pages
Global
From €4675EUR$4,950USD£3,976GBP
- Report
- April 2025
- 380 Pages
Global
From €5147EUR$5,450USD£4,378GBP
- Report
- May 2024
- 128 Pages
Global
From €6138EUR$6,499USD£5,220GBP
- Report
- May 2024
- 128 Pages
Global
From €6138EUR$6,499USD£5,220GBP
- Clinical Trials
- November 2024
- 180 Pages
Global
From €2361EUR$2,500USD£2,008GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3541EUR$3,750USD£3,012GBP
- Report
- April 2024
- 160 Pages
Global
From €4693EUR$4,969USD£3,991GBP
- Report
- February 2021
- 420 Pages
United States
From €2040EUR$2,160USD£1,735GBP
€2267EUR$2,400USD£1,928GBP
- Report
- March 2025
- 92 Pages
China
From €1700EUR$1,800USD£1,446GBP
- Report
- March 2024
- 397 Pages
Global
From €7508EUR$7,950USD£6,386GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1417EUR$1,500USD£1,205GBP
- Report
- August 2023
- 133 Pages
Global
From €7083EUR$7,500USD£6,024GBP
- Drug Pipelines
- July 2023
- 30 Pages
Global
From €2597EUR$2,750USD£2,209GBP
- Drug Pipelines
- January 2023
- 30 Pages
United States
From €2597EUR$2,750USD£2,209GBP
- Report
- October 2023
- 145 Pages
Global
From €2975EUR$3,150USD£2,530GBP
- Report
- October 2023
- 177 Pages
Global
From €4250EUR$4,500USD£3,615GBP

Aripiprazole is a medication used to treat mental disorders such as schizophrenia, bipolar disorder, and major depressive disorder. It is a dopamine partial agonist, meaning it works by stimulating dopamine receptors in the brain. Aripiprazole is also used to treat irritability and symptoms associated with autism spectrum disorder. It is available in both oral and injectable forms.
Aripiprazole is generally well-tolerated and has fewer side effects than other antipsychotic medications. It is also less likely to cause weight gain and metabolic changes than other antipsychotics.
The aripiprazole market is highly competitive, with many companies offering generic versions of the drug. Companies such as Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals are some of the major players in the market. Other companies such as Dr. Reddy's Laboratories, Lupin, and Torrent Pharmaceuticals also offer generic versions of the drug. Show Less Read more